Drug responses of imatinib mesylate-resistant cells: Synergism of imatinib with other chemotherapeutic drugs

Leukemia

Volumn 16, Issue 12, 2002, Pages 2349-2357

  Tipping, A J ^a   Mahon, F X ^b   Zafirides, G ^a   Lagarde, V ^b   Goldman, J M ^a   Melo, J V ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chronic myeloid leukemia; Combination chemotherapy; Drug resistance; Imatinib mesylate; ST1571; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CASPASE 3; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; ST 571; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL CRISIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RECURRENCE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; CONTROLLED STUDY; CROSS RESISTANCE; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMIA REMISSION; MONOTHERAPY; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; STEM CELL;

EID: 0036940590     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402775     Document Type: Article

References (40)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
3. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
7. Deininger MWN, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90: 3691-3698.
8. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
9. Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di NM, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23: 380-394.
10. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
11. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-1766.
12. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498-3505.
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
14. Kreil S, Muller MC, Lahaye T, La Rosee P, Corbin AS, Schoch C, Cross NCP, Berger U, Rieder H, Druker BJ, Gschaidmeier H, Hehlmann R, Hochhaus A. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. Blood 2001; 98: 435a.
15. Drexler HG. The Leukemia-Lymphoma Cell Line Facts Book. Academic Press: London, 2000.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
17. Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of. Cell Death Differ 1998; 5: 710-715.
18. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999-2007.
19. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15: 342-347.
20. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96: 3195-3199.
21. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96: 2246-2253.
22. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86: 3322-3326.
23. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999; 93: 4149-4153.
24. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol 2000; 18: 3513-3521.
25. Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 1968; 33: 129-135.
26. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-1205.
27. Gutierrez P, Delgado MD, Richard C, Moreau-Gachelin F, Leon J. Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells. Biochem Biophys Res Commun 1997; 240: 862-868.
28. Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 2001; 98: 3864-3867.
29. Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.
30. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.
31. Shah NP, Nicoll JM, Gorre ME, Paquette R, Ford J, Sawyers CL. Resistance to Gleevec: sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and de novo-resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis. Blood 2001; 98: 770a.
32. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472-3475.
33. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-491.
34. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-1862.
35. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood 2002; 100: 1068-1071.
36. Braess J, Wegendt C, Jahns-Streubel G, Kern W, Keye S, Unterhalt M, Schleyer E, Hiddemann W. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine. Br J Haematol 2000; 109: 388-395.
37. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
38. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 1998; 91: 1533-1541.
39. Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, Loo TL. Clinical pharmacology of homoharringtonine. Cancer Treat Rep 1986; 70: 1403-1407.
40. Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96: 549-556.